Fareon is pioneering a new class of biophysics therapies designed to noninvasively treat brain disorders through precisely calibrated electromagnetic fields. The company’s Fareon Restore platform delivers proprietary Microtesla Magnetic Therapy (MMT) in order to activate biological pathways associated with resolution of inflammation and oxidative stress, repair, and recovery in the brain. In clinical trials, MMT has been delivered through a lightweight Fareon Restore headset connected to a tabletop console.
Working alongside leading academic and clinical collaborators, Fareon combines biophysics, high-content imaging and AI to systematically map how physical fields influence biology, accelerating the discovery of therapeutic signals and their translation from cellular models to patients. A public benefit corporation, Fareon is developing therapies for clinical populations where existing treatment options remain limited. The company’s lead product is intended to be administered comfortably in an outpatient or home setting and has been well tolerated in clinical studies to date.
Learn more at fareon.co.
For use in coverage. Please reproduce verbatim where possible. MMT is an investigational device. It has not been cleared by the U.S. Food and Drug Administration, and is not available for sale. Safety and effectiveness findings of the first-in-human feasibility study (n=30) are to be established in larger controlled trials.
- Company
- Fareon, Inc. · Delaware PBC
- Headquarters
- San Francisco, CA
- Stage
- Clinical-stage biophysics
- Lead technology
- Microtesla Magnetic Therapy (MMT)
- First indication
- Long COVID cognitive impairment
- Clinical data
- First-in-human feasibility study completed (2025, Mount Sinai, n=30) and published (Brain Communications, 2026); multicenter study planned for early 2027
- Regulatory
- Investigational · not FDA-cleared
Logos, product images and headshots.
Published research
Microtesla magnetic therapy for cognitive impairment in long COVID: a randomized pilot study
Canori et al. · Peer-reviewed
Plasma Proteomics Identifies a Microtesla Magnetic Therapy Response Signature in Long COVID
Brady et al. · Preprint, currently under peer review
Transcranial microtesla magnetic fields suppress neuroinflammation and neuronal oxidative stress burden
Nguyen et al. · Peer-reviewed
Talk to the press office.
For interview requests, embargoed briefings, data and imagery.
- Media inquiries
- press@fareon.co
- Agency · Cuttlefish Communications
- Shira Derasmo · Chrystal Loyer
- Agency phone
- +1-917-280-2497
- Newsroom
- Releases and coverage






